NCT07376200

Single-ascending Dose Study of HEC-151 Injection

An I-phase Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics of a Single Dose of HEC-151 Injection in Healthy Chinese Participants in a Single-center, Randomized, Placebo (Single-blind) and Positive Control (Open-label) Study

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 81 (estimated)
• Sponsor: Sunshine Lake Pharma Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants

Conditions

• Healthy Adult Male

Interventions

Type	Name	Description
DRUG	HEC-151 Injection and placebo	Subcutaneous injection in the abdominal area
DRUG	Degludec insulin	Subcutaneous injection in the abdominal area

Timeline

• Start date: 2026-03-11
• Primary completion: 2026-09-05
• Completion: 2026-09-27
• First posted: 2026-01-29
• Last updated: 2026-01-29

Locations

1 site across 1 country: China